Impact of tumour volume on the potential efficacy of therapeutic vaccines.
about
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmTherapeutic cancer vaccines: past, present, and futureEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerScience gone translational: the OX40 agonist storySurgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer RecurrenceNovel non-AR therapeutic targets in castrate resistant prostate cancerTherapeutic cancer vaccines and combination immunotherapies involving vaccinationRole of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentProposed mechanisms of action for prostate cancer vaccines.A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Therapeutic cancer vaccines: current status and moving forward.Clinical evaluation of TRICOM vector therapeutic cancer vaccinesPoxviral vectors for cancer immunotherapyA pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.Therapeutic vaccines: the ultimate personalized therapy?Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsThe role of abiraterone in the management of metastatic castration-resistant prostate cancer.Prostate cancer vaccines.Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.Prostate cancer vaccines: the long road to clinical application.Tumor Vaccines for Malignant Gliomas.Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.Prostate cancer vaccines: Update on clinical development.Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report.Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.Hollow Structure Improved Anti-Cancer Immunity of Mesoporous Silica Nanospheres In Vivo.Sipuleucel-T and immunotherapy in the treatment of prostate cancer.Perspectives on the clinical development of immunotherapy in prostate cancer.Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
P2860
Q26747699-87E4B2C6-CB47-4C9B-9AD1-A3B05D0A4ED1Q26863283-6875D76E-AB57-4351-8274-81A03FA9FEB6Q27008070-F856FB3F-EB28-4A31-A561-0D4F09A35BA8Q27010542-4EC33865-4B75-4140-982A-D01E723B1C5EQ27022436-6D389B9B-4BD4-48CD-8579-56B3AB2A96D1Q27345519-DF1FB64A-1788-4A06-864A-95529ECE5581Q28383663-EC122A6D-5DE6-457F-A75D-FF99FB66066EQ28397609-B3308EE1-D924-496C-AC0D-D6EDC94E7AF5Q33718182-6325AD57-B66C-46E9-949F-FB70E78BE819Q35174754-982C868D-9B85-41DC-BED2-388F3A4C67CAQ35582228-D5B8306B-F78B-4D54-80F8-BDCBA8DFAEEBQ35756538-2FD1D008-6F7A-414E-80BA-7DCE2B140719Q35887319-13DB663B-FEB2-42FF-BA5E-2841B58D156AQ35894347-74D441AD-40AC-48A2-8147-760CC79DDEABQ36099965-E5C3763A-B05C-419D-9CA2-2308DA1176B0Q36350388-B5936D5F-CF55-40D2-92D1-74D9F6763FF0Q36444022-1A8687F7-53EF-44DA-929B-F59C46915B5EQ36888016-962DC02D-CC40-4543-A44F-287EE1DB31F1Q37017101-2A5C8805-7799-449D-A433-159E9BDE0895Q37068071-8C5A93C5-01D1-4977-8867-9287F0A3C293Q38002465-91EBBD4C-16A9-42A0-AFE7-CF1484B148B1Q38089935-0FB0E9B2-12B4-41C3-A0C1-2D9C3499E4F2Q38103581-6FC49E9B-5C78-42CA-B6DC-7CFABCC9B2B0Q38149916-B51D8521-4B6E-438E-8B96-F0981721D99BQ38187480-353E4554-6CD2-4439-AAF6-7A58D1885220Q38359237-BE4E3979-6921-4C6F-871C-8AC0E220E818Q39228039-F081AF93-AB85-47B1-85E4-8A2E8B0343EBQ40062688-AB6926B4-5B6B-4243-B135-E3D3AB42944EQ40241848-5F347B30-5074-46C9-BA57-A80B8B6AF9F0Q41220895-0C0E6FC2-333D-4498-98D6-D21667D03E0CQ41873286-50D60AC1-825B-4151-A7DD-F97266762255Q43297784-D5B48B8A-7F18-477B-A16F-B281216456FCQ46586294-8EE4A82A-C8EA-48DC-8C29-7183970289A7Q47630188-C627748C-D38A-4BE7-A1B3-6182AD6A63BDQ48238878-984C6608-9E7A-4D9C-BD7D-7AB9732D2F27Q51327516-F7094043-26DA-4848-9CC8-285F1FF31BDAQ53062915-02D3C9D5-24A2-4334-BD6C-2C64685436B2Q55029444-3DE600F9-E489-4D6A-9861-F57B631DA2C3Q55073226-5E71BC41-93B1-4509-85FD-D125C7651731Q57486475-1AA540FE-4A12-4455-8D59-39F81A12BC57
P2860
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@ast
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@en
type
label
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@ast
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@en
prefLabel
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@ast
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@en
P2093
P2860
P356
P1433
P1476
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
@en
P2093
P2860
P304
P356
10.3747/CO.V18I3.783
P577
2011-06-01T00:00:00Z